Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 3NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 24Myeloid 11Lymphoid 7Thoracic 4Other solid neoplasm 4Classical hematology 3Gastrointestinal 2Dermatologic 2Sarcoma 1Plasma cell 1Other neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1Endocrine 1CNS 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Melanoma 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Cyclophosphamide 80Paclitaxel 53Trastuzumab 41Tamoxifen 40Doxorubicin 39Specimen Handling 35Docetaxel 35Magnetic Resonance Spectroscopy 34Radiotherapy 33Taxes 30Fluorouracil 26Chemotherapy, Adjuvant 26Carboplatin 24Epirubicin 22Biopsy 22Filgrastim 21Neoadjuvant Therapy 19Methotrexate 19aldesleukin 17Peripheral Blood Stem Cell Transplantation 16Bevacizumab 14Anastrozole 14exemestane 13Lapatinib 13veliparib 12CMF regimen 12sargramostim 11Goserelin 11Fulvestrant 11Capecitabine 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Decitabine × Breast × Clear all
NCT00030615 2013-02-07

Decitabine in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
24 enrolled
BreastDermatologicGenitourinary

Urinary Bladder Neoplasms, Breast Neoplasms, Melanoma, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡